Clinical Study

Ucci-Hn-15-01- Phase II Investigation Of Adjuvant Combined Cisplatin And Radiation With Pembrolizumab In Resected Hnscc

Posted Date: May 15, 2019

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this research study is to determine the frequency and severity of side effects of Pembrolizumab when administered in combination with radiation alone or Cisplatin and radiation therapy (CRT) in patients undergoing adjuvant treatment for resected HNSCC.


To Be Eligible: Age 18 Or Older, Must Be Diagnosed With Resectable Hnscc. Nonpregnant/Breastfeeding, No Other Current Illness Or Malignancy


Cancer, Head And Neck, Hnscc, Resected, Ucci-Hn-15-01

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.